- Home
- LTRN vs ATNM Comparison
LTRN vs ATNM Comparison
Compare LTRN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- ATNM
- Stock Information
- Founded
- LTRN 2013
- ATNM 2000
- Country
- LTRN United States
- ATNM United States
- Employees
- LTRN N/A
- ATNM N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- ATNM Health Care
- Exchange
- LTRN Nasdaq
- ATNM Nasdaq
- Market Cap
- LTRN 49.9M
- ATNM 50.2M
- IPO Year
- LTRN 2020
- ATNM N/A
- Fundamental
- Price
- LTRN $3.80
- ATNM $1.37
- Analyst Decision
- LTRN Strong Buy
- ATNM Strong Buy
- Analyst Count
- LTRN 1
- ATNM 1
- Target Price
- LTRN $25.00
- ATNM $4.00
- AVG Volume (30 Days)
- LTRN 73.1K
- ATNM 218.5K
- Earning Date
- LTRN 11-12-2025
- ATNM 11-14-2025
- Dividend Yield
- LTRN N/A
- ATNM N/A
- EPS Growth
- LTRN N/A
- ATNM N/A
- EPS
- LTRN N/A
- ATNM N/A
- Revenue
- LTRN N/A
- ATNM $90,000.00
- Revenue This Year
- LTRN N/A
- ATNM N/A
- Revenue Next Year
- LTRN N/A
- ATNM N/A
- P/E Ratio
- LTRN N/A
- ATNM N/A
- Revenue Growth
- LTRN N/A
- ATNM 11.11
- 52 Week Low
- LTRN $2.55
- ATNM $1.03
- 52 Week High
- LTRN $6.12
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- LTRN 55.43
- ATNM 49.01
- Support Level
- LTRN $2.86
- ATNM $1.25
- Resistance Level
- LTRN $3.42
- ATNM $1.42
- Average True Range (ATR)
- LTRN 0.28
- ATNM 0.10
- MACD
- LTRN 0.03
- ATNM 0.01
- Stochastic Oscillator
- LTRN 99.80
- ATNM 40.54
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.